Elara Company Profile
Elara Pharmaservices Europe Ltd is part of a group of companies also comprising Elara Pharmaservices (UK) Ltd and Callisto Regulatory Consulting Ltd.
Elara Pharmaservices Europe Ltd was established in 2018 in response to the UK’s Brexit preparations and to ensure continued service for many of our Clients and is registered and based in Ireland.
The company holds an MIA granted by the HPRA in 2019. This enables it to support clients wishing to import Licensed products into the EEA. We hold our own Wholesale Dealers Authorisation (WDA) in Ireland via the HPRA.
Callisto Consulting was formed in 2004 offering Regulatory, PV and technical support to the Pharmaceutical Industry and Elara Pharmaservices Ltd was formed in 2012 as a subsidiary of Callisto to enable product release and offers Contract QP and Technical support to the Pharmaceutical Industry. It was granted an MIA in Feb 2013 & ManA in May 2013 to enable support to clients wishing to import Licensed Human & Veterinary products into the EEA. This may be restricted to the UK post Brexit and EEA importation will be done via Elara Pharmaservices Europe.
Our approach is one of flexibility and adaptability; we listen to our clients’ needs and requirements, making a real difference to the projects we are involved in which has been a key success factor for us.
The key differentiator between our approach and our competitors is how we use our experience and knowledge of what works operationally as well as in theory. Our expertise lies in executing projects in real world environments, recognising the fact that during any assignment we have an opportunity to positively impact our Clients operations.
This group of companies was built on the values of passion and commitment – our passion about what we do and our committed focus on our clients. We remain flexible to the changing needs of our clients and strive to deliver our services in a manner to suit their businesses.
We invest in people and infrastructure to enable us to be highly flexible, efficient and innovative.